This trial will test if adding darolutamide to ADT with a LHRHA can help prevent prostate cancer from coming back in men at very high risk of recurrence after radiation therapy.
1 Primary · 8 Secondary · Reporting Duration: Through study completion, an average of 5 years
Experimental Treatment
Non-Treatment Group
1100 Total Participants · 2 Treatment Groups
Primary Treatment: Darolutamide · Has Placebo Group · Phase 3
Age 18+ · Male Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:BC Cancer Agency (BCCA) Fraser Valley | 100.0% |
Met criteria | 100.0% |